Pathologic complete response in HER2-positive breast cancer patients receiving trastuzumab in neoadjuvant setting
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2019; 29 (2): 159-163
en Inglés
| IMEMR
| ID: emr-202931
ABSTRACT
Objective:
To compare the pathological complete response in human epidermal growth factor receptor type 2 [HER-2] positive breast cancer patients getting neoadjuvant chemotherapy with or without trastuzumab
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Idioma:
Inglés
Revista:
J. Coll. Physicians Surg. Pak.
Año:
2019
Similares
MEDLINE
...
LILACS
LIS